Business Context and Reporting Period
Company: Kintara Therapeutics, Inc. (filing as Kintara; proposed name change to TuHURA Biosciences, Inc. pending merger)
Reporting Period: Fiscal year ended June 30, 2024 (Form 10-K)
Business Overview: Kintara is a clinical-stage biopharmaceutical company focused on developing cancer therapies. Its lead candidate is REM-001, a photodynamic therapy (PDT) for cutaneous metastatic breast cancer (CMBC). The company operates with a "virtual" structure, employing one full-time employee and utilizing consultants.
Strategic Status: On April 2, 2024, Kintara entered into a definitive merger agreement with TuHURA Biosciences, Inc. Stockholders approved the merger on October 4, 2024. Upon consummation, Kintara stockholders will own approximately 2.85% of the combined company (5.45% including Contingent Value Rights), while TuHURA stockholders will own the remainder. The company also terminated the development of its VAL-083 candidate in October 2023 following negative topline results.
Key Financial Metrics
| Metric (in thousands) | Year Ended June 30, 2024 | Year Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,320) | $(14,649) |
| Net Loss Attributable to Common Stockholders | $(8,501) | $(15,019) |
| Research & Development Expenses | $2,663 | $9,311 |
| General & Administrative Expenses | $5,788 | $5,485 |
| Cash and Cash Equivalents (End of Period) | $4,909 | $1,535 |
| Working Capital | $3,269 | $188 |
| Accumulated Deficit | $(159,876) | $(151,375) |
| Cash Flow from Operating Activities | $(7,176) | $(11,865) |
| Cash Flow from Financing Activities | $10,570 | $1,852 |
Debt and Liquidity: The company has no long-term debt. Liquidity is supported by cash on hand and a $2 million NIH grant awarded in July 2023 to fund the REM-001 study. As of June 30, 2024, the company had $4.9 million in cash.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 43% (from $14.6 million to $8.3 million), primarily driven by a 71% reduction in R&D expenses.
- R&D Expense Decline: R&D expenses dropped from $9.3 million to $2.7 million. This was largely due to the termination of the VAL-083 glioblastoma study and reduced clinical development costs.
- Financing Activity: Net cash provided by financing activities increased significantly to $10.6 million (from $1.9 million), driven by $10.5 million in net proceeds from an At-The-Market (ATM) facility and $105,000 from a stock purchase agreement.
- Cash Position: Cash and cash equivalents increased by $3.4 million year-over-year, improving working capital from $188,000 to $3.3 million.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
The company does not provide traditional financial guidance. Management expects to complete enrollment of the 15-patient REM-001 study in the fourth calendar quarter of 2024. The company anticipates requiring significant additional funding to maintain operations beyond the current fiscal year if the merger is not consummated.
Management Commentary
Management has expressed substantial doubt about the company's ability to continue as a going concern within one year of the filing date due to recurring losses and negative cash flows. The company is pursuing the merger with TuHURA as a primary strategic alternative to secure its future. If the merger fails, the company plans to seek additional equity financing or strategic partnerships.
Risks and Contingencies
- Going Concern: The auditor has included an explanatory paragraph regarding the company's ability to continue as a going concern. Without the merger or new financing, the company may become insolvent.
- Nasdaq Compliance: The company received a notice of non-compliance with the Nasdaq Minimum Bid Price Requirement. It received an extension until December 9, 2024, and stockholders approved a reverse stock split (1-for-20 to 1-for-40) to regain compliance.
- Milestone Liabilities: The company has contingent payment obligations under the St. Cloud Agreement totaling up to $1 million in cash or stock upon specific clinical or regulatory milestones for REM-001, plus a 6% royalty on net sales.
- Merger Risks: The merger is subject to regulatory approval and closing conditions. If terminated, Kintara may owe a $1 million termination fee to TuHURA.
Investor Verification Checklist
- Merger Consummation: Verify the status of the merger with TuHURA Biosciences, Inc., including regulatory approvals and the expected closing date (mid-October 2024).
- Reverse Stock Split: Confirm the execution of the approved reverse stock split and its impact on share count and trading price.
- Going Concern Status: Assess the company's cash runway and the likelihood of securing additional capital if the merger does not close.
- REM-001 Clinical Progress: Monitor enrollment numbers for the 15-patient CMBC study and the achievement of the Contingent Value Rights (CVR) trigger (10 patients completing 8 weeks of follow-up by Dec 31, 2025).
- Nasdaq Listing: Verify continued compliance with Nasdaq listing requirements to avoid delisting.